Updates are available Correction dated 2021-06-09
Click to view Correction: https://doi.org/10.1038/s41375-021-01306-1
-
Authors
Kantarjian, Hagop M. https://orcid.org/0000-0002-1908-3307
Hughes, Timothy P.
Larson, Richard A. https://orcid.org/0000-0001-9168-3203
Kim, Dong-Wook https://orcid.org/0000-0003-3967-4267
Issaragrisil, Surapol
le Coutre, Philipp
Etienne, Gabriel
Boquimpani, Carla
Pasquini, Ricardo
Clark, Richard E. https://orcid.org/0000-0002-1261-3299
Dubruille, Viviane
Flinn, Ian W.
Kyrcz-Krzemien, Slawomira
Medras, Ewa
Zanichelli, Maria
Bendit, Israel
Cacciatore, Silvia
Titorenko, Ksenia
Aimone, Paola
Saglio, Giuseppe
Hochhaus, Andreas
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 2 October 2020
Revised: 2 November 2020
Accepted: 2 December 2020
First Online: 7 January 2021
Change Date: 9 June 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41375-021-01306-1
Compliance with ethical standards
:
: HMK, Grants, honoraria: AbbVie, Agios, Amgen, Immunogen, Pfizer. Grants: Ariad, Astex, BMS, Cyclacel, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis. Advisory boards: Actinium. Consulting: Novartis. Honoraria: Takeda. TPH, Grants, advisory boards, symposia: Novartis. Grants: BMS. RAL, Personal fees, clinical trials contracts: Novartis. D-WK, Grants: Novartis, BMS, Pfizer, ILYANG co. SI, none. PlC, Speaker, honoraria: Novartis, BMS, Pfizer, Incyte. GE, Personal fees, nonfinancial support: Novartis. Personal fees: BMS, Pfizer, Incyte. CB, Personal fees, speaker, advisory boards: Novartis. Personal fees, speaker: EMS. RP, none. REC, Grants, personal fees: Novartis. Grants, personal fees: BMS, Pfizer. Personal fees: Ariad/Incyte. VD, none. IWF, Grants, other funding: AbbVie, AstraZeneca, BeiGene, Gilead Sciences, Janssen, Juno Therapeutics, Kite Pharma, MorphoSys, Pharmacyclics, Roche, Seattle Genetics, Takeda, TG Therapeutics, Unum Therapeutics, Verastem. Other funding: Curio Science, Great Point Partners, Iksuda Therapeutics, Nurix Therapeutics, Yingli Pharmaceuticals. Grants: Acerta Pharma, Agios, ArQule, Calithera Biosciences, Celgene, Constellation Pharmaceuticals, Curis, F. Hoffmann-<scp>l</scp>a Roche Ltd, Forma Therapeutics, Forty Seven, Genentech, IGM Biosciences, Incyte, Infinity Pharmaceuticals, Karyopharm Therapeutics, Loxo, Merck, Novartis, Pfizer, Portola Pharmaceuticals, Teva, Trillium Therapeutics, Triphase Research & Development Corp., Rhizen Pharmaceuticals. SK, none. EM, none. MZ, none. IB, none. SC, Other funding: Novartis. KT, Novartis employee. PA, Novartis employee. GS, Personal fees: Novartis, BMS, ARIAD, Pfizer. AH, Research support, personal fees, nonfinancial support: Novartis. Research support, personal fees: BMS, Pfizer. Research support: Incyte.
: ENESTnd was conducted in accordance with the principles of the Declaration of Helsinki and local laws and regulations. Written informed consent was obtained from each patient. The study protocol was approved by the appropriate review board or ethics committee for each center. All authors had access to the data and analyzed the data in collaboration with the sponsor.
